To our knowledge, this is the first study to evaluate the role of coexisting mutations, taking into account all possible mutations available in the commercial molecular tests (ThyGeNEXT or ThyroSeq v3) in patients with thyroid cancer positive for TERT promoter mutations in the development of aggressive features. This evidence concerns the gene TERT and thyroid gland carcinoma.